P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA

• Xining Yang,
• Kathrin Krowiorz,
• Daelynn Buelow,
• Raj Bhayadia,
• Jessica Kohlschmidt,
• Deedra Nicolet,
• Tobias Maetzig,
• Caroline Pabst,
• Jeremy Hui,
• Arshia Shad,
• Sharon Gao,
• Maria Stephenson,
• Si Wei Wu,
• Marion van den Bosch,
• Leo Escano,
• Frances Lock,
• Afsaneh Panahi,
• Liam Macphee,
• Irina Maksakova,
• Amanda Amoah,
• Konstanze Döhner,
• Linda Fogelstrand,
• Ann-Kathrin Eisfeld,
• Sanaz Yahyanejad,
• Michel Janicot,
• Jan-Henning Klusmann,
• Sharyn Baker,
• Christopher Oakes,
• Arefeh Rouhi,
• Florian Kuchenbauer

Affiliations

Xining Yang

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Kathrin Krowiorz

2 University Hospital Ulm, Division of Hematology and Oncology, Ulm, Germany

Daelynn Buelow

3 The Ohio State University, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, Columbus, United States

Raj Bhayadia

4 Goethe University Frankfurt, Department of Pediatrics, Frankfurt, Germany

Jessica Kohlschmidt

5 The Ohio State University, Clara D. Bloomfield Center for Leukemia Outcomes Research, Comprehensive Cancer Center, Columbus, United States

Deedra Nicolet

5 The Ohio State University, Clara D. Bloomfield Center for Leukemia Outcomes Research, Comprehensive Cancer Center, Columbus, United States

Tobias Maetzig

6 Hannover Medical School, Institute of Experimental Hematology, Hannover, Germany

Caroline Pabst

7 University Hospital Heidelberg, Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany

Jeremy Hui

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Arshia Shad

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Sharon Gao

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Maria Stephenson

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Si Wei Wu

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Marion van den Bosch

8 InteRNA Technologies BV, Utrecht, The Netherlands

Leo Escano

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Frances Lock

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Afsaneh Panahi

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Liam Macphee

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Irina Maksakova

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Amanda Amoah

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Konstanze Döhner

2 University Hospital Ulm, Division of Hematology and Oncology, Ulm, Germany

Linda Fogelstrand

9 Sahlgrenska University Hospital, Department of Clinical Chemistry, Gothenburg, Sweden

Ann-Kathrin Eisfeld

5 The Ohio State University, Clara D. Bloomfield Center for Leukemia Outcomes Research, Comprehensive Cancer Center, Columbus, United States

Sanaz Yahyanejad

8 InteRNA Technologies BV, Utrecht, The Netherlands

Michel Janicot

8 InteRNA Technologies BV, Utrecht, The Netherlands

Jan-Henning Klusmann

4 Goethe University Frankfurt, Department of Pediatrics, Frankfurt, Germany

Sharyn Baker

3 The Ohio State University, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, Columbus, United States

Christopher Oakes

5 The Ohio State University, Clara D. Bloomfield Center for Leukemia Outcomes Research, Comprehensive Cancer Center, Columbus, United States

Arefeh Rouhi

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada

Florian Kuchenbauer

1 British Columbia Cancer Research Institute, Terry Fox Laboratory, Vancouver, Canada